CCL5 production in DLBCL is a posttumoral transformation event. (A) CCL5 and CD68 mRNA expression in tumors among GC, ABC, and unknown (Unk.) DLBCL subtypes from the GSE10846 data set. Differences were analyzed by 1-way analysis of variance. (B) DLBCL cell lines were phenotyped by flow cytometry for the indicated markers. Blue lines correspond to control Ig staining. (C) ELISA for CCL5 in the supernatant of nonstimulated (NS), CD40L/α-BCR, and TNF-stimulated tonsillar B-cell subsets (upper panel). Reverse transcription PCR analysis of CCL5 mRNA expression in CD19⁺IgD⁺CD38⁻ naive, CD19⁺CD38⁺ GC, and CD19⁺IgD⁻CD38⁻ memory B cells (lower panel). OCI-Ly18 was used as a positive control. Data are representative of 3 patients with tonsillitis. (D) Quantitative reverse transcription PCR analysis for CCL5 mRNA in CCL5⁻ DLBCL cell lines treated with decitabine, TSA, or DMSO vehicle control. A value of 1 was arbitrarily assigned to DMSO-treated CCL5⁺ OCI-Ly18. Data (mean ± standard deviation) are representative of 3 independent experiments. *P < .05 vs DMSO-treated group. ns, not significant.